Omalizumab to Accelerate a Symptom-driven Multi-food OIT

Phase 2 Active not recruiting 90 enrolled Philippe Bégin Centre de recherche du Centre hospitalier universitaire de Sherbrooke · collab Centre hospitalier de l'Université de Montréal (CHUM) · collab The Hospital for Sick Children · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will determine the dose-related efficacy of a 20-week treatment of omalizumab started 8 weeks before the onset of a symptom-driven multi-food oral immunotherapy (OIT) protocol at decreasing time to OIT maintenance dose. Two dosages of omalizumab will be compared to placebo during an oral immunotherapy protocol for three simultaneous food allergens.

Timeline

Start: 2019-11-11
Primary completion: 2025-12
Completion: 2026-03

Publications

Langlois A, Lavergne MH, Leroux H, Killer K, Azzano P, Paradis L, Samaan K, Lacombe-Barrios J, Masse B, Des Roches A, Begin P. Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy. Allergy Asthma Clin Immunol. 2020 Apr 17;16:25. doi: 10.1186/s13223-020-00419-z. eCollection 2020.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Omalizumab	Monoclonal antibody	8 mg/kg	—
Subject	Omalizumab	Monoclonal antibody	16 mg/kg	—

Omalizumab to Accelerate a Symptom-driven Multi-food OIT

Summary

Timeline

Publications

Drugs

Indications